[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sherief Abd-Elsalam\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":427},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,41,63,86,105,121,141,160,178,201,222,241,259,277,297,315,332,353,374,391,407],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100421315","phase-3-role-of-bumetanide-in-treatment-of-autism-100421315",false,"NCT04766177","Role of Bumetanide in Treatment of Autism","Role of Bumetanide in Treatment of Autism Spectrum Disorder in Children","Inclusion Criteria:\n\n1. All patients with ASD diagnosed by CARS rating Scale⩾30.\n2. Age of patients range between (3-12) years.\n\nExclusion Criteria:\n\n* Patients with ASD associated with neurological antecedents (including epilepsies and febrile seizures), hepatic, renal dysfunction or electrocardiogram abnormalities and syndromatic children(Rett).","ALL","3 Years","12 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Role of bumetanide in Autism",[27],"Autism","RECRUITING","2021-02-19",{"date":31,"type":32},"2021-02-23","ACTUAL",{"date":34,"type":32},"2021-01-01",{"date":36,"type":21},"2030-12-01",{"name":38,"class":39},"Sherief Abd-Elsalam","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":40},"100416613","phase-3-clinical-study-evaluating-beta-blockers-use-and-fracture-risk-in-patients-with-primary-osteoporosis-100416613","NCT04704947","Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis","Clinical Study Evaluating Selective or Nonselective Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis","Inclusion Criteria:\n\n* • Male \\& female osteoporotic patient aged ≥ 50 years\n\n  * Hypertensive \\& normotensive patients\n  * BMD T-score ≥ 2.5 or more SD below peak bone mass\n\nExclusion Criteria:\n\n* Patients on drugs that may improve osteoporosis disease state such as:\n\n  * Angiotensin converting enzyme inhibitor (ACEI) or Angiotensin receptor blockers (ARBs), Thiazide diuretic, Nitrates, Spironolactone, Statins.\n\nPatients on drugs that may worsen osteoporosis disease state such as:\n\n• Corticosteroids, Loop diuretics, Anticonvulsants, Antidepressants, Aromatase inhibitors, Thyroid replacement therapy and Proton pump inhibitors.","50 Years",{"count":50,"type":21},50,[24],"Clinical study evaluating selective or nonselective beta blockers use and fracture risk in patients with primary osteoporosis",[54],"Beta Blocker Toxicity","2021-01-09",{"date":57,"type":32},"2021-01-12",{"date":59,"type":32},"2017-10-01",{"date":61,"type":21},"2030-10-01",{"name":38,"class":39},{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":70,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":40},"100400873","phase-2-carvedilol-versus-endoscopic-band-ligation-for-primary-prophylaxis-of-oesophageal-variceal-bleeding-100400873","NCT04499898","Carvedilol Versus Endoscopic Band Ligation for Primary Prophylaxis of Oesophageal Variceal Bleeding","Randomized Controlled Trial of Carvedilol Versus Endoscopic Band Ligation for Primary Prophylaxis of Oesophageal Variceal Bleeding in Cirrhotic Patients With Arterial Hypertension","Inclusion Criteria:\n\n* • Aged \\>18 years\n\n  * Cirrhotic patients with arterial hypertension\n  * Endoscopic evidence of medium\u002Flarge-sized esophageal varices\n\nExclusion Criteria:\n\n* • History of variceal bleeding or previous primary prevention of varices.\n\n  * Portal vein thrombosis or previous porto-systemic shunts as TIPS.\n  * Patients on drugs affecting portal pressure (beta blockers, nitrates).\n  * Advanced cardiovascular disease including acute myocardial infarction, atrio-ventricular block, congestive heart failure, chronic peripheral ischemia, severe bradycardia.\n  * Patients with severe respiratory diseases (COPD, bronchial asthma).\n  * Uncontrolled diabetes mellitus\n  * Renal impairment\n  * Hepatocellular carcinoma\n  * Allergy to carvedilol\n  * Pregnancy or lactation","18 Years",{"count":72,"type":21},306,[74,24],"PHASE2","Carvedilol versus endoscopic band ligation for primary prophylaxis of oesophageal variceal bleeding in cirrhotic patients with arterial hypertension",[77],"Esophageal Varices","2020-08-01",{"date":80,"type":32},"2020-08-05",{"date":82,"type":32},"2018-10-01",{"date":84,"type":21},"2030-12-10",{"name":38,"class":39},{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":104,"locationsCount":40},"100400872","potential-role-of-gastric-lavage-by-paraffin-oil-in-acute-aluminum-phosphide-poisoning-100400872","NCT04499885","Potential Role of Gastric Lavage by Paraffin Oil in Acute Aluminum Phosphide Poisoning","Potential Role of Gastric Lavage by Paraffin Oil in Acute Aluminum Phosphide Poisoning: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* • Patients with symptomatic acute aluminum phosphide poisoning\n\nExclusion Criteria:\n\n* • Pregnant and lactating women\n\n  * Asymptomatic patients with history of acute aluminum phosphide exposure.\n  * Patients with ingestion or exposure to other substances in addition to aluminum phosphide.\n  * Patients with other major medical conditions (e.g. cardiovascular disease, renal or hepatic failure).\n  * Patients with previous medical intervention (had gastric lavage in any medical center before admission).\n  * Patients with disturbed consciousness level\n  * Patients with post cardiac arrest cases",{"count":94,"type":21},62,[96],"NA","Potential Role of Gastric Lavage by Paraffin Oil in Acute Aluminum Phosphide Poisoning.",[99],"Toxicity, Drug",{"date":80,"type":32},{"date":102,"type":32},"2020-06-01",{"date":84,"type":21},{"name":38,"class":39},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":70,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":109,"conditions":115,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":119,"leadSponsor":120,"locationsCount":40},"100400862","phase-3-efficacy-of-nucleo-cmp-forte-in-traumatic-brain-injury-in-pediatrics-100400862","NCT04499755","Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics","Efficacy of Nucleo CMP Forte in Traumatic Brain Injury in Pediatrics: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Children with traumatic brain injury: Moderate and Severe.\n\nExclusion Criteria:\n\n* Underlying CNS disorders,",{"count":113,"type":21},100,[24],[116],"Brain Injuries",{"date":80,"type":32},{"date":102,"type":32},{"date":84,"type":21},{"name":38,"class":39},{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":22,"phases":130,"briefSummary":125,"conditions":131,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":40},"100379202","phase-3-pantoprazole-in-cisplatin-nephrotoxicity-100379202","NCT04217512","Pantoprazole in Cisplatin Nephrotoxicity","Possible Protective Effect of Pantoprazole in Cisplatin Induced Nephrotoxicity in Patients With Head and Neck Cancer","Inclusion Criteria:\n\n* Patients with head and neck cancer\n\nExclusion Criteria:\n\n* GFR less than 59.\n* DM\n* Elevated liver enzymes more than 3 fold.",{"count":129,"type":21},60,[24],[132],"Oncology","2020-01-02",{"date":135,"type":32},"2020-01-03",{"date":137,"type":32},"2019-05-01",{"date":139,"type":21},"2030-12-30",{"name":38,"class":39},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":148,"maxAge":70,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":145,"conditions":152,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":159,"locationsCount":40},"100379101","phase-3-role-of-coenzyme-q-in-adhd-in-children-100379101","NCT04216186","Role of Coenzyme Q in ADHD in Children","Role of Coenzyme Q in Treatment of Attention Deficit Hyperactivity Disorder in Children","Inclusion Criteria:\n\n* Patients with ADHD\n\nExclusion Criteria:\n\n* Comorbidities like Autism, Anxiety, Obsessive compulsive disorder.","2 Years",{"count":150,"type":21},40,[24],[153],"ADHD","2019-12-29",{"date":133,"type":32},{"date":157,"type":32},"2018-11-01",{"date":36,"type":21},{"name":38,"class":39},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":70,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":172,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":40},"100379102","role-of-point-of-care-ultrasound-in-endotracheal-tube-placement-100379102","NCT04216199","Role of Point of Care Ultrasound in Endotracheal Tube Placement","Role of Point of Care Ultrasound in Confirmation of Endotracheal Tube Placement in Children","Inclusion Criteria:\n\n* Children below 18 years needing endotracheal intubation.\n\nExclusion Criteria:\n\n* Age more than 18 years.\n* Patients with significant neck or lung pathology.\n* Patients with elective intubation",{"count":150,"type":21},[96],"Role of point of care ultrasound in endotracheal tube placement in children",[171],"Endotracheal Tube Wrongly Placed During Anesthetic Procedure",{"date":133,"type":32},{"date":174,"type":32},"2019-11-01",{"date":176,"type":21},"2030-12-20",{"name":38,"class":39},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":185,"maxAge":70,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":40},"100373592","phase-4-effect-of-gaba-on-adhd-and-seizures-in-children-with-epilepsy-100373592","NCT04144439","Effect of GABA on ADHD and Seizures in Children With Epilepsy.","Effect of Gamma Aminobutyric Acid on ADHD and Seizures in Children With Epilepsy.","Inclusion Criteria:\n\n* Epilepsy\n* ADHD\n\nExclusion Criteria:\n\n* Epilepsy without ADHD","4 Years",{"count":187,"type":21},30,[189],"PHASE4","Effect of GABA on ADHD and seizures in Children with epilepsy.",[192],"Epilepsy","2019-10-29",{"date":195,"type":32},"2019-10-30",{"date":197,"type":32},"2018-07-01",{"date":199,"type":21},"2028-12-01",{"name":38,"class":39},{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":22,"phases":209,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":40},"100241604","phase-3-study-of-orphenadrine-in-the-treatment-of-muscle-cramps-in-patients-with-cirrhosis-100241604","NCT02423395","Study of Orphenadrine' in the Treatment of Muscle Cramps in Patients With Cirrhosis","Randomized Study of Orphenadrine' in the Treatment of Muscle Cramps in Patients With Cirrhosis","Inclusion Criteria:\n\n* Cirrhosis\n* Muscle cramps( ≥3 cramps per week )\n\nExclusion Criteria:\n\n* • Allergy to orphenadrine\n\n  * Renal impairment\n  * Pregnant and lactating women\n  * Peripheral vascular disease\n  * Peripheral neuropathy\n  * Medications as calcium channel blockers, conjugated estrogens and naproxen. Glaucoma Prostatic enlargement",{"count":113,"type":21},[24],"Muscle cramps are common in patients with liver disease and associated with significantly diminished quality of life. Patients with cirrhosis often experience muscle cramps with varied frequency and severity. The exact mechanisms by which they occur remain unclear, although a number of pathophysiological events unique to liver disease may contribute. Clinical studies have identified alterations in 3 areas: nerve function, energy metabolism, and plasma volume\u002Felectrolytes (1) Orphenadrine is an anticholinergic drug with prominent central nervous system (CNS) and peripheral actions used to treat painful muscle spasms and other similar conditions. The combination of anticholinergic effects and CNS penetration make orphenadrine useful for pain of all etiologies, including from: radiculopathy, muscles, and headaches. \\[3,4\\]",[212,213],"Liver Cirrhosis","Muscle Cramps","2019-06-06",{"date":216,"type":32},"2019-06-07",{"date":218,"type":4},"2015-01",{"date":220,"type":21},"2028-12",{"name":38,"class":39},{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":22,"phases":231,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":239,"leadSponsor":240,"locationsCount":40},"100359905","phase-3-citicoline-as-neuroprotector-in-preterm-100359905","NCT03966170","Citicoline as Neuroprotector in Preterm","Efficacy of Citicoline as Neuroprotector in Preterm; A Randomized Controlled Trial","Inclusion Criteria:\n\n* Preterm on CPAP or ventilator\n\nExclusion Criteria:\n\n* Multiple congenital anomalies","1 Month",{"count":150,"type":21},[24],"Citicoline as neuroprotector in preterm",[234],"Pre-Term","2019-05-24",{"date":237,"type":32},"2019-05-29",{"date":137,"type":32},{"date":220,"type":21},{"name":38,"class":39},{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":229,"maxAge":248,"enrollmentInfo":249,"targetDuration":4,"studyType":22,"phases":250,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":254,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":258,"locationsCount":40},"100359891","phase-3-docosahexaenoic-acid-on-breath-holding-spells-in-children-100359891","NCT03965988","Docosahexaenoic Acid on Breath Holding Spells in Children","Effect of Docosahexaenoic Acid on Breath Holding Spells in Children: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Children with newly diagnosed sprlls\n\nExclusion Criteria Other treatment as iron and piracetam","5 Years",{"count":129,"type":21},[24],"DHA on Breath Holding Spells",[253],"Breath Holding Attack",{"date":237,"type":32},{"date":256,"type":32},"2018-05-01",{"date":220,"type":21},{"name":38,"class":39},{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":229,"enrollmentInfo":266,"targetDuration":4,"studyType":22,"phases":267,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":271,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":40},"100358590","phase-3-citicoline-as-neuroprotector-in-neonates-exposed-to-hypoxia-100358590","NCT03949049","Citicoline as Neuroprotector in Neonates Exposed to Hypoxia","Efficacy of Citicoline as Neuroprotector in Neonates Exposed to Hypoxia: A Randomized Controlled Trial","Inclusion Criteria:\n\n* neonates with hypoxia.\n\nExclusion Criteria:\n\n* hypoxic ischemic encephalopathy",{"count":150,"type":21},[24],"Citicoline as neuroprotector in neonates exposed to hypoxia: A randomized controlled trial",[270],"Neonatal Hypoxia",{"date":237,"type":32},{"date":273,"type":32},"2019-02-01",{"date":275,"type":21},"2029-12-01",{"name":38,"class":39},{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":16,"minAge":70,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":22,"phases":286,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":296,"locationsCount":40},"100356799","phase-3-clinical-study-evaluating-vildagliptin-versus-vildagliptinmetformin-on-nafld-with-dm-100356799","NCT03925701","Clinical Study Evaluating Vildagliptin Versus Vildagliptin\u002FMetformin on NAFLD With DM","Clinical Study Evaluating the Effectiveness of Vildagliptin Versus Vildagliptin\u002FMetformin on NAFLD With DM","Inclusion Criteria:\n\n* NAFLD and type 2 DM\n\nExclusion Criteria:\n\n* Viral hepatitis.\n* Child score more than 6.\n* renal impairment.",{"count":285,"type":21},120,[24],"Clinical study evaluating vildagliptin versus vildagliptin\u002Fmetformin on NAFLD with DM.",[289],"dm","2019-04-26",{"date":292,"type":32},"2019-04-29",{"date":294,"type":32},"2019-04-01",{"date":220,"type":21},{"name":38,"class":39},{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":16,"minAge":70,"maxAge":4,"enrollmentInfo":304,"targetDuration":4,"studyType":22,"phases":305,"briefSummary":306,"conditions":307,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":313,"leadSponsor":314,"locationsCount":40},"100356796","phase-3-mebendazole-as-adjuvant-treatment-for-colon-cancer-100356796","NCT03925662","Mebendazole as Adjuvant Treatment for Colon Cancer","Clinical Study Evaluating Mebendazole as Adjuvant Therapy in Patients With Colorectal Cancer","Inclusion Criteria:\n\n* Colorectal cancer stage 4.\n\nExclusion Criteria:\n\n* Agranulocytosis\n* Pregnancy\n* Allergy to mebendazole.",{"count":150,"type":21},[24],"mebendazole treating colon cancer",[308],"Colorectal Cancer","2019-04-22",{"date":311,"type":32},"2019-04-24",{"date":294,"type":32},{"date":220,"type":21},{"name":38,"class":39},{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":16,"minAge":70,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":22,"phases":324,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":328,"startDateStruct":329,"completionDateStruct":330,"leadSponsor":331,"locationsCount":40},"100356800","phase-3-impact-of-p53-and-sirt1-in-type-2-diabetes-100356800","NCT03925714","Impact of P53 and SIRT1 in Type 2 Diabetes","Investigating the Impact of p53 and SIRT1 in the Development of Type 2 DM Through the Treatment of Prediabetic Individuals by Either Nigetella Salivata or Metformin","Inclusion Criteria:\n\n* Prediabetic subjects.\n\nExclusion Criteria:\n\n* Confirmed diabetes.\n* Hepatic or renal impairment.",{"count":323,"type":21},90,[24],"Investigating the impact of p53 and SIRT1 in the development of type 2 DM",[327],"DM",{"date":311,"type":32},{"date":294,"type":32},{"date":220,"type":21},{"name":38,"class":39},{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":339,"sex":16,"minAge":70,"maxAge":340,"enrollmentInfo":341,"targetDuration":4,"studyType":22,"phases":342,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":350,"leadSponsor":352,"locationsCount":40},"100345021","utility-of-some-novel-biomarkers-of-patients-with-chronic-heart-failure-100345021","NCT03772275","Utility of Some Novel Biomarkers of Patients With Chronic Heart Failure","Clinical and Economical Study Evaluating the Utility of Some Novel Biomarkers of Patients With Chronic Heart Failure","Inclusion Criteria:\n\n* NYHA-Class II-IV\n\nExclusion Criteria:\n\n* Liver or renal dysfunction. --DM",true,"75 Years",{"count":129,"type":21},[96],"Clinical and Economic study of some new biomarkers in chronic heart failure.",[345],"Heart Failure","2018-12-08",{"date":348,"type":32},"2018-12-11",{"date":82,"type":32},{"date":351,"type":21},"2027-10",{"name":38,"class":39},{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":11,"sex":16,"minAge":70,"maxAge":360,"enrollmentInfo":361,"targetDuration":4,"studyType":22,"phases":363,"briefSummary":364,"conditions":365,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":371,"leadSponsor":373,"locationsCount":40},"100344900","phase-3-statins-and-arbs-on-rheumatoid-activity-100344900","NCT03770702","Statins and ARBs on Rheumatoid Activity","Investigational and Comparative Study Between the Anti-inflammatory Effectof Both Angiotensin Reeptor Blockers and Statins on Rheumatoid Arthritis Disease Activity on Egyptian Patients","Inclusion Criteria:\n\n* Rheumatoid arthritis.\n\nExclusion Criteria:\n\n* Pregnant or lactating\n* Hepatic or renal impairment.","65 Years",{"count":362,"type":21},45,[24],"Investigational and comparative study between the anti-inflammatory effectof both angiotensin reeptor blockers and statins on rheumatoid arthritis disease activity on Egyptian patients",[366],"Rheumatoid Arthritis","2018-12-07",{"date":369,"type":32},"2018-12-10",{"date":82,"type":32},{"date":372,"type":21},"2026-12-01",{"name":38,"class":39},{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":16,"minAge":381,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":22,"phases":383,"briefSummary":378,"conditions":384,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":386,"startDateStruct":387,"completionDateStruct":388,"leadSponsor":390,"locationsCount":40},"100344918","phase-3-effect-of-some-drugs-on-liver-fibrosis-100344918","NCT03770936","Effect of Some Drugs on Liver Fibrosis","Clinical Study Evaluating the Efficacy of Renin Angiotensin System Inhibitors on the Extent of Liver Fibrosis in Patients With Chronic Hepatitis C","Inclusion Criteria:\n\n* chronic hepatitis C\n\nExclusion Criteria:\n\n* Acute hepatitis\n* Thalassemia","20 Years",{"count":362,"type":21},[24],[385],"Liver Fibroses",{"date":369,"type":32},{"date":82,"type":32},{"date":389,"type":21},"2027-11",{"name":38,"class":39},{"id":392,"slug":393,"hasResults":11,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":11,"sex":16,"minAge":70,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":22,"phases":400,"briefSummary":401,"conditions":402,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":403,"startDateStruct":404,"completionDateStruct":405,"leadSponsor":406,"locationsCount":40},"100344917","phase-3-effect-of-some-drugs-on-rheumatoid-arithritis-activity-100344917","NCT03770923","Effect of Some Drugs on Rheumatoid Arithritis Activity","Clinical Study Evaluating the Effect of Histamine 1 Receptor Antagonist and Leukotreine Receptor Antagonist on Patients With Rheumatoid Arithritis","Inclusion Criteria:\n\n* Rheumatoid arthritis\n\nExclusion Criteria:\n\n* liver or renal disease",{"count":399,"type":21},75,[24],"Effect of Some Drugs on Rheumatoid Arithritis Activity.",[366],{"date":369,"type":32},{"date":82,"type":32},{"date":351,"type":21},{"name":38,"class":39},{"id":408,"slug":409,"hasResults":11,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":11,"sex":16,"minAge":70,"maxAge":4,"enrollmentInfo":414,"targetDuration":4,"studyType":22,"phases":415,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":419,"lastUpdatePostDateStruct":420,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":40},"100335411","phase-3-ppi-versus-histamine-antagnists-as-adjuvant-to-chemotherapy-100335411","NCT03647072","PPI Versus Histamine Antagnists as Adjuvant to Chemotherapy","Comparative Clinical and Biochemical Study Evaluating the Effect of Proton Pump I Nhibitors Versus Histamine 2 Receptor Antagonists as an Adjuvant With Chemotherapy in Patients With Non-hodgkin Lymphoma.","Inclusion Criteria:\n\n* DLBCL Lymphoma subtype --No comorbid disease\n\nExclusion Criteria:\n\n* Pregnancy\n* Peptic ulcer\n* Severe cardiac disease\n* Osteoporosis",{"count":129,"type":21},[24],"The study is a Comparative Clinical and Biochemical Study Evaluating the effect of Proton Pump I nhibitors versus histamine 2 Receptor antagonists as an adjuvant with chemotherapy in patients with Non-hodgkin Lymphoma.",[418],"Lymphoma","2018-08-23",{"date":421,"type":32},"2018-08-27",{"date":423,"type":32},"2018-08-01",{"date":425,"type":21},"2027-12",{"name":38,"class":39},""]